Causes and evaluation of mildly elevated liver transaminase levels

American Family Physician

Volumn 84, Issue 9, 2011, Pages 1003-1008

  Oh, Robert C ^a   Hustead, Thomas R ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALANINE AMINOTRANSFERASE; ALLOPURINOL; ALPHA 1 ANTITRYPSIN; AMFEBUTAMONE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BACLOFEN; CERULOPLASMIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; ISONIAZID; KETOCONAZOLE; LISINOPRIL; LOSARTAN POTASSIUM; METHOTREXATE; MICROSOME ANTIBODY; OMEPRAZOLE; PARACETAMOL; PLACEBO; RIFAMPICIN; RISPERIDONE; SMOOTH MUSCLE ANTIBODY; TRAZODONE; VALPROIC ACID;

ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG OVERDOSE; ECHOGRAPHY; HEMOCHROMATOSIS; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER TOXICITY; MUSCLE DISEASE; NONALCOHOLIC FATTY LIVER; PHYSICAL EXAMINATION; PROTEIN ELECTROPHORESIS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; THYROID DISEASE; TOXIC HEPATITIS; WILSON DISEASE;

EID: 80355149181     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101(1):76-82.
2. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-967.
3. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367-1384.
4. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266-1271.
5. Morisco F, Pagliaro L, Caporaso N, et al.; University of Naples Federico II, Italy. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. Dig Liver Dis. 2008;40(7):585-598.
6. Krier M, Ahmed A. The asymptomatic outpatient with abnormal liver function tests. Clin Liver Dis. 2009;13(2):167-177.
7. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steato-hepatitis. Gastroenterology. 2008;134(6):1682-1698.
8. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006;73(11):1961-1968.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346 (16):1221-1231.
10. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evalutation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21(1):87-97.
11. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantifcation of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51(3):433-445.
12. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595-602.
13. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006; 354(7):731-739.
14. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87-93.
15. Heard KJ, Green JL, Dart RC. Serum alanine aminotransferase elevation during 10 days of acetaminophen use in nondrinkers. Pharmacotherapy. 2010;30(8):818-822.
16. National Institute on Alcohol Abuse and Alcoholism. Alcohol Alert. No. 27 PH 355 January 1995. http://pubs.niaaa.nih.gov/publications/aa27. htm. Accessed February 22, 2011.
17. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41(4):690-695.
18. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-60C.
19. Bays H. Statin safety: an overview and assessment of the data 2005. Am J Cardiol. 2006; 97(8A):6C-26C.
20. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R; Pravastatin in Chronic Liver Disease Study Investigators. Effcacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatol-ogy. 2007;46(5):1453-1463.
21. Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and effcacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916-1922.
22. World Health Organization. Hepatitis B. http://www.who.int/mediacentre/ factsheets/fs204/en/index.html. Accessed October 7, 2010.
23. Centers for Disease Control and Prevention. Viral hepatitis statistics and surveillance. http://www.cdc.gov/hepatitis/statistics. Accessed February 7, 2011.
24. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK; Clinical Effcacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. [published correction appears in Ann Intern Med. 2006;144(5):380]. Ann Intern Med. 2005;143(7):517-521.
25. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin def-ciency. N Engl J Med. 2009;360(26):2749-2757.
26. Teckman JH, Lindblad D. Alpha-1-antitrypsin defciency: diagnosis, patho-physiology, and management. Curr Gastroenterol Rep. 2006;8(1):14-20.
27. Manns MP, Czaja AJ, Gorham JD, et al.; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-2213.
28. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54-66.
29. Roberts EA, Schilsky ML; American Association for Study of Liver Diseases. Diagnosis and treatment of Wilson disease: an update. Hepatol-ogy. 2008;47(6):2089-2111.
30. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology. 2002; 123(4):1364-1366.
31. Lazo M, Selvin E, Clark JM. Brief communication: clinical implications of short-term variability in liver function test results. [published correction appears in Ann Intern Med. 2009;150(7):504]. Ann Intern Med. 2008;148(5):348-352.
32. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastro-enterol. 1999;94(10):3010-3014.